The Decibel

A growing number of Canadians are struggling with fertility, and the business helping people make babies is booming. The global fertility services market was valued at more than $21-billion in 2021 and is projected to more than quadruple by 2031. As more hopeful parents turn toward services like in-vitro fertilization – or IVF – and surrogacy to conceive, Globe investigative journalist Kathryn Blaze Baum worries they may not know exactly what they’re signing up for.

Today, Baum shares her first-hand story and reporting into the fertility industry in her new book, In Fertility: The Story of a Miracle and the Big Business Behind It. Kathryn will explain what it’s like to navigate assisted reproductive technology, its high costs financially and emotionally, and what she thinks needs to change about how Canada handles fertility.

This episode originally aired April 6, 2026.

Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The auto sector is at the heart of trade discussions between Canada and the U.S.

Canada’s auto sector has been hit hard over the past year with tariffs from U.S. President Donald Trump. How the U.S. was planning on dealing with the auto industry was one of the reasons the trade deal between the two countries fell apart over the weekend.

So today, The Globe’s economics reporter, Mark Rendell, explains why trade discussions focus so heavily on the auto industry, what impact the tariffs have had, and what it means for a sector that is already struggling.

Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Canada-U.S. trade war is in full effect.

On Tuesday, the federal government announced retaliatory tariffs against the United States. U.S. steel, seafood, dishwashers, forks, and all manner of other things are facing tariffs of 15, 25 or even 50 per cent.

Jason Kirby, from The Globe’s Report on Business, tells us how Canada is striking back in this latest front of the trade war.

Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

After trade talks broke down between Ottawa and Washington, U.S. President Donald Trump implemented 50-per-cent tariffs on $28-billion dollars worth of Canadian goods. Over the weekend, Prime Minister Mark Carney vowed to retaliate with dollar-for-dollar countertariffs, which are set to take effect after Labour Day. On Monday, President Trump announced the U.S. would also be doubling its tariffs on Canadian auto parts and steel to 50 per cent come Jan. 1, 2027.

As the trade war escalates and deepens, Canadian businesses — already struggling under existing levies — are bracing for even more pain as uncertainty becomes the norm.

Today, the Globe’s capital markets reporter, Jameson Berkow, is here. He’ll tell us what he’s hearing from business leaders, how these new levies and countertariffs will impact Canada’s economy, and how businesses are preparing for a lengthy trade war.

Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plasma is the golden fluid part of the blood and it’s used to make life-saving medications for people with immune deficiencies. In Canada, plasma donors were historically volunteers, for the most part. While paid donation was legal in some provinces, it wasn’t especially common.

But in 2022, Canadian Blood Services partnered with Grifols, a Spanish company, to expand paid plasma donation. Now, they operate 17 sites across six provinces. After the deaths of two donors in the past year, however, Health Canada has been examining the company’s procedures. Earlier this month, Grifols announced they were pausing operations.

Chris Hannay covers the business of health for The Globe. Today, he’s here to talk about what we know about Grifols’ temporary closure, what we’ve learned about the deaths, and what this all means for Canada’s access to plasma-based medication.

Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.